Claims for Patent: 7,771,706

Summary for Patent: 7,771,706

Title:	Method for monitoring protein translation
Abstract:	Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed. Also disclosed is a method for monitoring protein translation related to angiogenesis.
Inventor(s):	Norfray; Joseph F. (Glenview, IL)
Assignee:	Receptomon, LLC (Glenview, IL)
Application Number:	11/622,321
Patent Claims:	1. A method for monitoring protein translation comprising: administering an amount of an angiogenesis effector molecule to an animal or animal cells; measuring, by Magnetic Resonance Spectroscopy, the amount of Choline present in an angiogenic tissue, tissues or cells before and after administering the angiogenesis effector molecule; correlating any change in the amount of Choline measured to a change in protein translation; wherein the angiogenesis effector is selected from the group consisting of VEGF receptor tyrosine kinase inhibitors, monoclonal antibodies to growth factor receptors, VEGF toxin conjugate, dominant negative VEGF-2, soluble VEGFR (VEGF-TRAP) and antisense oligonucleotides, growth factor transforming kinases, farnesyl transferase inhibitors, agents targeting tumor suppressors, agents that inhibit proliferation of endothelial cells, antibody and peptide integrin inhibitors, plasmin inhibitors, urokinase-type plasminogen activator inhibitors, matrix metalloproteinase inhibitors, cyclooxygenase inhibitors, lipoxygenase inhibitors, and inhibitors of mitogenic effects, and any combination thereof. 2. The method of claim 1, wherein the protein translation arises due to a change in the amount of rough endoplasmic reticulums. 3. The method of claim 1, wherein the angiogenesis effector molecule causes an interruption in an up-regulated intracellular organelle. 4. The method of claim 3, wherein the interruption in the up-regulated intracellular organelle decreases the number of secretory granules. 5. The method of claim 3, wherein the interruption in the up-regulated intracellular organelle decreases the number of transporting vesicles. 6. The method of claim 1, wherein the angiogenesis effector molecule causes an interruption in a function of the Golgi apparatus, lysosomes, endoplasmic reticulum, mitochondrion, nucleus, peroxisomes or combinations thereof. 7. The method of claim 1, wherein the angiogenesis effector stimulates angiogenesis. 8. The method of claim 1, wherein the angiogenesis effector inhibits angiogenesis. 9. The method of claim 8, wherein the angiogenesis effector interrupts one or more pathways selected from the group consisting of a growth factor signaling pathway, an integrin/protease pathway, a coagulation/fibrinolysis pathway, and an inflammatory signaling pathway. 10. The method of claim 9, wherein the angiogenesis effector is selected from the group consisting of SU5416, SU6668, cetuximab, gefitinib, erlotinib, canertinib, EKB-569, lapatinib, IMC-C225, ABX-EGF, HuMax-EGFR, DC101, suramin, gleevec, herceptin, p-53 (PRIMA-1), thalidomide, squalamine, anti-.alpha.vB3 integrin antibody, anti-.alpha.vB5 integrin antibody, cyclic peptide inhibitor of integrin .alpha.vB3//.alpha.vB5, cilengitide, fumagallin, TNP-470, EMD 121974, .alpha.2-antiplasmin, .alpha.2-macroglobulin, kininostatin, BMS275291, COL-3, marimastat, neovastat, solimastat, angiostatin, endostatin, antithrombin fragments, fibrinogen-E, fibrin-D, thrombospondin-1, platelet factor-4, low molecular weight heparins, rofecoxib, celecoxib, and interferon-.alpha. and .beta., and any combination thereof. 11. The method of claim 1, wherein the MRS is based on the resonance of nuclei selected from the group consisting of .sup.31P, .sup.1H, .sup.13C, .sup.23Na, and any combination thereof. 12. The method of claim 11, wherein the MRS is based on .sup.13C resonance. 13. The method of claim 1, wherein measuring the amount of Choline comprises measuring the height of a peak corresponding to Choline. 14. The method of claim 1, wherein measuring the amount of Choline comprises measuring the area under a peak corresponding to Choline. 15. The method of claim 1, wherein measuring the amount of Choline comprises measuring the ratio of the height of a peak corresponding to Choline relative to the height of peak of an internal standard. 16. The method of claim 15, wherein the internal standard is total creatine when the MRS is based on .sup.1H resonance. 17. The method of claim 15, wherein the internal standard is adenosine triphosphate (ATP) when the MRS is based on .sup.31P resonance. 18. The method of claim 1, wherein measuring the amount of Choline comprises measuring the ratio of the area under a peak corresponding to Choline relative to the area under a peak of an internal standard. 19. The method of claim 18, wherein the MRS is based on .sup.1H resonance and the internal standard is total creatine. 20. The method of claim 18, wherein the MRS is based on .sup.13C resonance and the internal standard is total creatine. 21. A method for monitoring protein translation comprising: administering an amount of an angiogenesis effector molecule to an animal or animal cells; measuring, by Magnetic Resonance Spectroscopy, the amount of Choline present in an angiogenic tissue, tissues or cells before and after administering the angiogenesis effector molecule; correlating any change in the amount of Choline measured to a change in protein translation; wherein the angiogenesis effector is selected from the group consisting of SU5416, SU6668, cetuximab, gefitinib, erlotinib, canertinib, EKB-569, lapatinib, IMC-C225, ABX-EGF, HuMax-EGFR, DC101, suramin, gleevec, herceptin, p-53 (PRIMA-1), thalidomide, squalamine, anti-.alpha.vB3 integrin antibody, anti-.alpha.vB5 integrin antibody, cyclic peptide inhibitor of integrin .alpha.vB3//.alpha.vB5, cilengitide, fumagallin, TNP-470, EMD 121974, .alpha.2-antiplasmin, .alpha.2-macroglobulin, kininostatin, BMS275291, COL-3, marimastat, neovastat, solimastat, angiostatin, endostatin, antithrombin fragments, fibrinogen-E, fibrin-D, thrombospondin-1, platelet factor-4, low molecular weight heparins, rofecoxib, celecoxib, and interferon-.alpha. and .beta., and any combination thereof.

Details for Patent 7,771,706

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2025-02-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-02-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-02-08